CHU Helora — Clinical Trial Site

114 Registered trials

56 Currently recruiting

Organisation

CHU Helora

Location

La Louviere, Belgium

Identifier

ORG-100042541

Address

Rue Samiette 1, 1400, Belgium

Departments

#1006: Onco-Hématologie
#40059: Rhumatologie
0506
056002-Hématologie
1605: Hematology
3703; Reumatology
6044: Rheumatology
7102 Rhumatologie
BE30005:Hematology/Hematologie
cardiologie
Cardiology
Clinical Research Unit
Department of Oncology
Department of Endocrinology
Department of Hematology
Department of Medical Oncology
Department of Oncology
Department of Oncology and Hematology
Endocrinologie – Diabetologie
Gastro-enterology
Gastro-oncology
Gastroenterology
Hematologie
Hematology
Hematology Department
Hôpital Ambroise Paré
Hopital de La Louviere - Site Jolimont, Oncologie
Internal Medicine
Medical Oncology
N/A
NA
Neurology
Oncolgy
Oncologie
Oncologie médicale
Oncologie-Hématologie
Oncology
Oncology and Hematology
Oncology and Hematology departments
Orthopedic surgery and traumatology
Otorhinolaryngology
Pneumology
Pulmonology
Radiotherapy
Rheumatology
Service de Recherche Clinique (SeReC), Level 5A

Clinical trials at this site (114)

Search interface

MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
Multicentric study evaluating the usefulness of early PSMA PET scan in metastatic renal cancer requiring standard immunotherapy treatment. Pending

2024-517098-26-00 metastatic clear cell Renal Carcinoma Cell 4
A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient… Pending

2024-517621-54-00 High-risk non-muscle invasive bladder cancer (NMIBC) af 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot… Pending

2025-523575-36-00 Locally advanced head and neck squamous cell carcinoma 4
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Recruiting

2025-521792-31-01 Homozygous Familial Hypercholesterolemia (HoFH) 5 2026-04-07
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Effect of immunotherapy in patients with oligo-metastatic (limited number of metastases) non-small cell lung cancer after being treated with… Recruiting

2023-508741-40-00 Non-small cell lung cancer 10 2025-01-14
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant… Recruiting

2024-517762-42-01 recalcitrant lower limb nonunion 7 2018-08-02
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Recruiting

2025-521587-35-00 Metastatic colorectal cancer 5 2026-06-03
Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting

2025-522107-18-00 Locally advanced or metastatic Non-Small Cell Lung Canc 4 2026-05-19
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 TROP2 NMR-positive advanced or metastatic non-squamous 5 2026-04-01
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2026-03-12
Radiopharmaceutical treatment of advanced kidney cancer Recruiting

2024-517899-38-00 Clear Cell Renal Cell Carcinoma (ccRCC) 4 2026-02-25
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Patients aged 18-65 years old with newly diagnosed prev 10 2026-01-05
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-520927-26-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-11-24
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Recruiting

2024-514693-47-01 EGFR mutated locally advanced or metastatic non-small c 11 2025-10-28